These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 24209520)

  • 1. Re: Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial.
    Taneja SS
    J Urol; 2013 Dec; 190(6):2094. PubMed ID: 24209520
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial.
    Bahl A; Oudard S; Tombal B; Ozgüroglu M; Hansen S; Kocak I; Gravis G; Devin J; Shen L; de Bono JS; Sartor AO;
    Ann Oncol; 2013 Sep; 24(9):2402-8. PubMed ID: 23723295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
    Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
    Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cabazitaxel--a next-generation taxane for the treatment of patients with metastatic castration-resistant prostate cancer].
    Ecstein-Fraisse E; Su Z
    Gan To Kagaku Ryoho; 2014 Jul; 41(7):817-22. PubMed ID: 25131866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study.
    Aggarwal R; Bryce A; Ryan CJ; Harzstark A; Derleth C; Kim W; Friedlander T; Lin AM; Rodvelt-Bagchi T; Dhawan M; Zhang L; Lee M; Siebeneck E; Hough J; Small EJ
    Urol Oncol; 2017 Apr; 35(4):149.e7-149.e13. PubMed ID: 28161323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of life and pain relief in men with metastatic castration-resistant prostate cancer on cabazitaxel: the non-interventional 'QoLiTime' study.
    Hofheinz RD; Lange C; Ecke T; Kloss S; Linsse B; Windemuth-Kieselbach C; Hammerer P; Al-Batran SE
    BJU Int; 2017 May; 119(5):731-740. PubMed ID: 27618249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer.
    Bracarda S; Gernone A; Gasparro D; Marchetti P; Ronzoni M; Bortolus R; Fratino L; Basso U; Mazzanti R; Messina C; Tucci M; Boccardo F; Cartenì G; Pinto C; Fornarini G; Mattioli R; Procopio G; Chiuri V; Scotto T; Dondi D; Di Lorenzo G
    Future Oncol; 2014 May; 10(6):975-83. PubMed ID: 24295376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme.
    Heidenreich A; Bracarda S; Mason M; Ozen H; Sengelov L; Van Oort I; Papandreou C; Fossa S; Hitier S; Climent MA;
    Eur J Cancer; 2014 Apr; 50(6):1090-9. PubMed ID: 24485664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metastatic castration-resistant prostate cancer: changing landscape with cabazitaxel.
    Fernández O; Afonso J; Vázquez S; Campos B; Lázaro M; León L; Antón Aparicio LM
    Anticancer Drugs; 2014 Mar; 25(3):237-43. PubMed ID: 24217332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cabazitaxel for the therapy of metastatic castration-resistant prostate cancer in the aftermath of the CHAARTED trial.
    Pal SK; Sonpavde G
    BJU Int; 2015 Dec; 116(6):839-40. PubMed ID: 26542327
    [No Abstract]   [Full Text] [Related]  

  • 11. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
    de Bono JS; Oudard S; Ozguroglu M; Hansen S; Machiels JP; Kocak I; Gravis G; Bodrogi I; Mackenzie MJ; Shen L; Roessner M; Gupta S; Sartor AO;
    Lancet; 2010 Oct; 376(9747):1147-54. PubMed ID: 20888992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase 1 Trial of Cabazitaxel Combined With 188Re-Hydroxyethylidene Diphosphonate in Patients With Metastatic Castration-Resistant Prostate Cancer Who Progressed on or After a Docetaxel-Containing Treatment: The ReCab Trial.
    van Dodewaard-de Jong JM; Bouman-Wammes EW; Bloemendal HJ; Verheul HMW; de Klerk JMH; van den Eertwegh AJM
    Clin Nucl Med; 2017 Jun; 42(6):415-420. PubMed ID: 28263212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of mitoxantrone plus prednisone versus prednisone alone in metastatic castrate-resistant prostate cancer after docetaxel failure.
    Green AK; Corty RW; Wood WA; Meeneghan M; Reeder-Hayes KE; Basch E; Milowsky MI; Dusetzina SB
    Oncologist; 2015 May; 20(5):516-22. PubMed ID: 25888270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clarification to provide further understanding of the conduct and design of TROPIC: A Phase 3 trial of cabazitaxel versus mitoxantrone in patients with metastatic castration-resistant prostate cancer.
    De Bono J; Shen L; Sartor O
    Arch Ital Urol Androl; 2016 Mar; 88(1):72-3. PubMed ID: 27072184
    [No Abstract]   [Full Text] [Related]  

  • 15. Reply to: Clarification to provide further understanding of the conduct and design of TROPIC: A Phase 3 trial of cabazitaxel versus mitoxantrone in patients with metastatic castration-resistant prostate cancer.
    Perletti G
    Arch Ital Urol Androl; 2016 Mar; 88(1):74-5. PubMed ID: 27072185
    [No Abstract]   [Full Text] [Related]  

  • 16. The Combination of 80 Years of Age and Metastatic Castration-Resistant Prostate Cancer Remain an Uphill Battle: A Case Report with Cabazitaxel as a Double-Edged Sword.
    Méry B; Trone JC; Moriceau G; Falk AT; Guillot A; Pacaut C; Collard O; Magné N
    Chemotherapy; 2014; 60(5-6):300-1. PubMed ID: 25997418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapidly progressive disease in a castration-resistant prostate cancer patient after cabazitaxel discontinuation.
    Di Lorenzo G; Buonerba C; de Placido S
    Anticancer Drugs; 2015 Feb; 26(2):236-9. PubMed ID: 25340916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer.
    Angelergues A; Maillet D; Fléchon A; Ozgüroglu M; Mercier F; Guillot A; Le Moulec S; Gravis G; Beuzeboc P; Massard C; Fizazi K; de La Motte Rouge T; Delanoy N; Elaidi RT; Oudard S
    Eur J Cancer; 2014 Jun; 50(9):1602-9. PubMed ID: 24725337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of De Ritis (Aspartate Transaminase/Alanine Transaminase) Ratio as a Significant Prognostic But Not Predictive Biomarker in Japanese Patients with Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel.
    Miyake H; Matsushita Y; Watanabe H; Tamura K; Suzuki T; Motoyama D; Ito T; Sugiyama T; Otsuka A
    Anticancer Res; 2018 Jul; 38(7):4179-4185. PubMed ID: 29970547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical perspectives: practical insights from clinical experience with cabazitaxel in Australia.
    Parente P; Gurney H; Ng S; Bahre M
    Asia Pac J Clin Oncol; 2015 Sep; 11(3):199-207. PubMed ID: 25856659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.